HC Wainwright & Co. Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $83
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) but lowered the price target from $92 to $83.
August 02, 2024 | 9:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained its Buy rating on Apellis Pharmaceuticals but lowered the price target from $92 to $83.
The maintained Buy rating suggests continued confidence in Apellis Pharmaceuticals' prospects, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100